BeiGene Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

BeiGene yıllık ortalama 1.3% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19.3% annual. Gelirler yılda ortalama 44.9% oranında büyüyor .

Anahtar bilgiler

1.3%

Kazanç büyüme oranı

11.1%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	44.9%
Özkaynak getirisi	-24.8%
Net Marj	-25.5%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion

Nov 06

BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat

Aug 22

Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

Aug 14

BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

Aug 09

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Jun 21

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

May 30

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

Apr 21

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

Mar 08

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Jan 31

Gelir ve Gider Dağılımı

BeiGene nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:BGNE Gelir, gider ve kazançlar (CNY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	23,508	-5,993	12,221	13,464
30 Jun 24	22,504	-3,806	12,013	13,534
31 Mar 24	19,948	-5,664	11,583	13,218
31 Dec 23	17,452	-6,258	10,684	12,624
30 Sep 23	15,649	-7,128	10,238	21,148
30 Jun 23	13,139	-12,570	9,985	17,935
31 Mar 23	10,694	-13,166	9,014	14,072
31 Dec 22	9,766	-13,820	8,819	11,315
30 Sep 22	8,892	-15,291	8,943	0
30 Jun 22	7,160	-13,600	8,062	0
31 Mar 22	5,561	-12,424	7,001	0
31 Dec 21	7,475	-9,264	6,292	9,273
30 Sep 21	6,851	-8,641	5,751	0
30 Jun 21	6,115	-8,569	5,059	0
31 Mar 21	5,653	-7,645	4,424	0
31 Dec 20	2,016	-10,608	3,918	0
30 Sep 20	1,804	-10,268	3,635	0
30 Jun 20	1,588	-9,852	3,388	0
31 Mar 20	2,850	-8,108	3,100	0
31 Dec 19	2,982	-6,605	2,703	0
30 Sep 19	3,073	-5,923	2,268	0
30 Jun 19	2,980	-4,570	1,794	0
31 Mar 19	1,634	-4,945	1,504	0
31 Dec 18	1,363	-4,635	1,344	0
30 Sep 18	1,083	-3,468	1,032	0
30 Jun 18	2,143	-1,611	775	0
31 Mar 18	1,700	-923	519	0
31 Dec 17	1,551	-606	407	0
30 Sep 17	1,465	-209	290	-34
30 Jun 17	0	-1,249	221	0
31 Mar 17	3	-1,018	177	0
31 Dec 16	7	-828	140	0
30 Sep 16	38	-726	98	35
30 Jun 16	47	-581	80	0
31 Mar 16	52	-445	60	0
31 Dec 15	57	-371	47	0
30 Sep 15	35	-214	38	0
30 Jun 15	66	-182	48	0
31 Mar 15	73	-162	45	0
31 Dec 14	81	-113	43	0
31 Dec 13	67	-45	19	0

Kaliteli Kazançlar: BGNE şu anda kârlı değil.

Büyüyen Kar Marjı: BGNE şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: BGNE kârlı değildir, ancak son 5 yılda zararlarını yılda 1.3% oranında azaltmıştır.

Büyüme Hızlandırma: BGNE 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: BGNE kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: BGNE hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -24.79% ) sahiptir.

BeiGene Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

BeiGene, Ltd. to Report Q3, 2024 Results on Nov 13, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

BeiGene, Ltd. to Report Q2, 2024 Results on Aug 07, 2024

BeiGene, Ltd. to Report First Half, 2024 Results on Aug 30, 2024

First quarter 2024 earnings released: US$2.41 loss per share (vs US$3.35 loss in 1Q 2023)

Recent updates

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion

New minor risk - Shareholder dilution

BeiGene, Ltd. Announces Passing Away of Donald Glazer, A Board Member and the Chair of the Nominating and Corporate Governance Committee

Co-Founder notifies of intention to sell stock

BeiGene, Ltd. to Report Q3, 2024 Results on Nov 13, 2024

Global Head of R&D notifies of intention to sell stock

BeiGene, Ltd. Appoints Shalini Sharp to Board of Directors and Member of the Audit Committee, Effective September 27, 2024

President & COO notifies of intention to sell stock

BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy

President & COO notifies of intention to sell stock

BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat

Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

Consensus estimates of losses per share improve by 31%

BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

BeiGene, Ltd. to Report Q2, 2024 Results on Aug 07, 2024

Beigene, Ltd. Appoints Aaron Rosenberg as the Principal Financial Officer, Effective from July 22, 2024

BeiGene, Ltd. Announces CFO Changes

BeiGene, Ltd. to Report First Half, 2024 Results on Aug 30, 2024

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

First quarter 2024 earnings released: US$2.41 loss per share (vs US$3.35 loss in 1Q 2023)

BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

BeiGene, Ltd., Annual General Meeting, Jun 05, 2024

Co-Founder recently sold US$7.5m worth of stock

Co-Founder notifies of intention to sell stock

BeiGene, Ltd. to Report Q1, 2024 Results on May 11, 2024

BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Co-Founder notifies of intention to sell stock

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

BeiGene, Ltd. Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

BeiGene, Ltd. to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024

BeiGene, Ltd. Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Full year 2023 earnings released: US$8.45 loss per share (vs US$19.43 loss in FY 2022)

BeiGene, Ltd. Announces Adults Living with Chronic Lymphocytic Leukemia in Ontario and Quebec Now Have Access, Through Public Reimbursement, to BRUKINSA® (Zanubrutinib)

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Now 21% undervalued after recent price drop

Beigene, Ltd. Announces Board Changes

Now 22% undervalued after recent price drop

Forecast to breakeven in 2026

BeiGene, Ltd. Announces FDA Approves Label Update for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

BeiGene, Ltd. Receives European Commission Approval for BRUKINSA®? (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Co-Founder notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 11%

Consensus EPS estimates upgraded to US$11.07 loss

Beigene, Ltd. Receives Positive Recommendation from Nice in U.K. for Adult Patients with Chronic Lymphocytic Leukemia

BeiGene, Ltd. Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeli

Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

Consensus EPS estimates fall by 18%

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

U.S. FDA Accepts Biologics License Application in First-Line Advanced ESCC

BeiGene, Ltd. Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA(R)

Beigene, Ltd. Announces Change of Chair of Audit Committee

New minor risk - Profitability

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$3.64 loss per share (vs US$5.51 loss in 2Q 2022)

Beigene Announces Positive CHMP Opinion for Tislelizumab as Treatment for Advanced or Metastatic ESCC